ArticleGut2007
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Article in Gut, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2009Guideline
- Article
- Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Clinical pharmacokinetics · 2016Review
- Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses.Pharmacology research & perspectives · 2015Article
- Article
- Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.Mediators of inflammation · 2015Review
- Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis.International journal of colorectal disease · 2013Article
- State-of-the-art medical prevention of postoperative recurrence of Crohn's disease.Nature reviews. Gastroenterology & hepatology · 2013Review
- Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011?Frontline gastroenterology · 2011Review
- Diagnosis and management of fistulizing Crohn's disease.Nature clinical practice. Gastroenterology & hepatology · 2009Review
- Biologic therapy for inflammatory bowel disease comes of age.Current gastroenterology reports · 2008Article
- The optimization of immunosuppressive and biologic cotherapies in inflammatory bowel disease.Gastroenterology & hepatology · 2008Article
- Biologic therapy for inflammatory bowel disease comes of age.Current gastroenterology reports · 2007Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.